NFKB1 and hepatocellular carcinoma: Dehydroxymethylepoxyquinomicin (DHMEQ) has been derived from the structure of an antibiotic epoxyquinomicin C. Several studies evaluated the effect of DHMEQ as a NF-κB inhibitor in human hepatoma cell lines [106,107,108,109].